Clinical Trials Logo

Filter by:
NCT ID: NCT04145414 Completed - Mri Clinical Trials

Cerebrospinal Fluid Movements Through Interventricular Foramina in Phase Contrast Magnetic Resonance Imaging (PC-MRI)

MLCSFIV
Start date: June 13, 2019
Phase: N/A
Study type: Interventional

Assess the reproductibility of PC-MRI for cerebrospinal fluid movements through the interventricular foramina on volunteer subjects.

NCT ID: NCT04145219 Completed - Clinical trials for Allergic Rhinitis Due to House Dust Mite

House Dust Mite Allergy Trial In Children

MATIC
Start date: October 12, 2019
Phase: Phase 3
Study type: Interventional

A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)

NCT ID: NCT04144413 Completed - Clinical trials for Dry Eye Disease With Severe Keratitis

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Start date: May 31, 2019
Phase: Phase 3
Study type: Interventional

The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis® (1mg/mL ciclosporin) eye drops administered once daily

NCT ID: NCT04143503 Completed - Critical Illness Clinical Trials

Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients

Start date: November 5, 2019
Phase:
Study type: Observational

The aim of this study is to characterise the use of clinical nutrition support, especially of parenteral nutrition that is administered directly into a vein, in adult patients with critical illness. The study wants to assess nutritional balance (that means the ratio of calories and protein prescribed to calories and protein actually received). Furthermore, it wants to evaluate whether the nutrition received has influence on the patients' clinical outcome, with focus on measures of physical function, such as capability of conducting daily living activities. As the study is "observational", no specific medications or treatments will be provided as part of the study to the patients. Study patients will be observed during their stay on an intensive care unit, for a maximum duration of 15 days. Furthermore, questions on the well-being of the patients will be asked via telephone interviews 30 and 90 days after their admission to the intensive care unit. Data of approximately 1250 patients will be collected and evaluated in this study, from approximately 100 hospitals in 11 European countries (Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, Sweden and United Kingdom).

NCT ID: NCT04143438 Completed - Clinical trials for Patellofemoral Dislocation

Assessment of Surgical Correction of Patello-femoral Instability by EOS 3D Kinematics

EOS-FP2017
Start date: June 2, 2020
Phase: N/A
Study type: Interventional

Assessment of surgical correction of patello-femoral instability by EOS 3D kinematics

NCT ID: NCT04142801 Completed - Clinical trials for Neurocognitive Disorders

Efficacy of the Memory Motivation (MEMO) Web Application Training

MeMo
Start date: May 5, 2017
Phase: N/A
Study type: Interventional

Memory, attentional, and behavioural symptoms are the clinical hallmarks of Neurocognitive disorders (NCD) such as Alzheimer's disease and related disorders. The World Health Organisation (WHO) guidelines for risk reduction of cognitive decline and dementia indicate that Cognitive training may be offered to older adults with normal cognition and with mild cognitive impairment to reduce the risk of cognitive decline and/or dementia. The use of Information and Communication Technologies (ICT) in the health domain is progressively expanding. The Alzheimer Innovation Association have developed MeMo (Memory Motivation) a free web application that can be used at home by patients. The objective of the present study was to assess the effectiveness of employing the MeMo platform on cognitive performance in patients suffering from NCD.

NCT ID: NCT04142684 Completed - Clinical trials for Unilateral Diaphragmatic Paralysis

Phrenic Nerve Conduction Study to Diagnose Unilateral Diaphragmatic Paralysis

ENMG-DIAPH
Start date: January 24, 2020
Phase:
Study type: Observational

The study aims as the principal objective to compare two approaches to diagnosis unilateral diaphragmatic paralysis: transdiaphragmatic pressure (Pdi) measurement versus phrenic nerve conduction (NPC) study. The secondary objective of the study is the strengths and weaknesses of different tests. Diagnostic threshold values.

NCT ID: NCT04142580 Completed - Lumbago Clinical Trials

Correlation Between RMI of Degenerative Disk Disease and Reduction of Pain After Disk-infiltration Treatments

MODISC
Start date: November 13, 2019
Phase:
Study type: Observational

The primary objective of the study is to demonstrate the difference in the reduction of pain at 1 month after intradiscal infiltration of corticosteroids depending on symmetrical or asymmetrical active discopathies with MRI examination. The difference should be judged significant if it ⩾ 2 points.

NCT ID: NCT04142567 Completed - Neoplasm Clinical Trials

Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation

CHOPIN
Start date: February 11, 2020
Phase:
Study type: Observational

The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation. The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases. The primary endpoint is the prevalence of pharmacist interventions among patients who are going to receive an oral targeted therapy or cancer chemotherapy or immunotherapy

NCT ID: NCT04142515 Completed - Clinical trials for Giant Cell Arteritis

Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)

CARTECEL
Start date: February 1, 2020
Phase:
Study type: Observational

Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness. Treatment: corticosteroid therapy, which is effective in the vast majority of cases. Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences: - Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity. - Requires additional immunosuppressive treatment.